# Methotrexate-Inadequate Response Study

> **NCT00559585** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 2492 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** Subcutaneous (SC) Abatacept
- **DRUG:** Intravenous (IV) Abatacept

## Key facts

- **NCT ID:** NCT00559585
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-11
- **Final completion:** 2014-09
- **Target enrollment:** 2492 (ACTUAL)
- **Last updated:** 2015-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00559585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00559585, "Methotrexate-Inadequate Response Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00559585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*